Interstitial Lung Disease Associated with Immune Checkpoint Inhibitors in Gastrointestinal Cancer Treatment: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database and EudraVigilance Database
This pharmacovigilance study analyzing FAERS and EudraVigilance data reveals that immune checkpoint inhibitor-induced interstitial lung disease in gastrointestinal cancer patients exhibits distinct, agent-specific risk profiles regarding gender, onset timing, and geographic variation, underscoring the need for risk-stratified monitoring to mitigate its high fatality rate.